

Regimen Reference Order – LYMP – cladribine (Hairy Cell Leukemia)

ARIA: LYMP – [cladribine (HCL)]

Planned Course: Once weekly for 6 weeks

Indication for Use: Hairy Cell Leukemia

CVAD: At Provider's Discretion

Proceed with treatment if:

Day 1

- *Proceed regardless of blood counts*

Days 8, 15, 22, 29 and 36

- *ANC and platelets are the same or greater than pre-treatment value (prior to Day 1)*
- ❖ *Contact Hematologist if parameters not met*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP – cladribine (Hairy Cell Leukemia)

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1, 8, 15, 22, 29 and 36		
cladribine	0.14 mg/kg	IV in normal saline 500 mL over 2 hours once weekly

All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See LYMP DSG – Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Baseline

- HIV serology and Hepatitis B serology

Days 1, 8, 15, 22, 29 and 36

- CBC, serum creatinine, urea, liver enzymes and uric acid as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
sulfamethoxazole-trimethoprim	800/160 mg	Orally twice daily on Saturdays and Sundays only
valACYclovir	500 mg	Orally once daily
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Remind patient to take valACYclovir (shingles prophylaxis) and sulfamethoxazole-trimethoprim (*Pneumocystis jirovecii* pneumonia prophylaxis) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- valACYclovir and sulfamethoxazole-trimethoprim continue while on treatment and for 3 months after discontinuation of treatment due to risk of prolonged immunosuppression
- Patients on cladribine require irradiated blood products